SCHEDULE: Balyasny Asset Management Discloses 9.99% Stake in Lexeo Therapeutics

Balyasny Asset Management L.P. and its affiliates have reported beneficial ownership of 9.99% of Lexeo Therapeutics, Inc. common stock, totaling 7,844,311 shares.

Summary

• Balyasny Asset Management L.P. (BAM), along with its related entities BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively hold a significant stake in Lexeo Therapeutics, Inc.
• The total beneficial ownership amounts to 7,844,311 shares of common stock, representing 9.99% of the class.
• This ownership level is based on 78,521,634 shares outstanding as of May 7, 2026.
• The reported shares include 2,412,742 directly held shares and 5,431,569 shares issuable from the exercise of warrants.
• The exercise of warrants is subject to a 'Beneficial Ownership Limitation' which caps ownership at 9.99% to prevent changes in control.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but controlled stake by Balyasny Asset Management L.P. and its affiliates in Lexeo Therapeutics, Inc. The 9.99% ownership level suggests confidence without triggering control implications.

Positives

• Significant investment by a major asset management firm (Balyasny Asset Management L.P.) indicates potential confidence in Lexeo Therapeutics' future prospects.
• The ownership stake of 9.99% is substantial, demonstrating a notable commitment to the company.
• The structure of the filing and the ownership limitation suggest a strategic investment rather than an attempt to gain control, which can be viewed positively by existing management and shareholders.

Negatives

• The filing does not disclose any negative financial performance or operational issues; it is purely an ownership disclosure.
• The 'Beneficial Ownership Limitation' on warrants means that the full potential ownership is capped, limiting further upside from warrant exercise without triggering reporting thresholds.

Risks

• The 'Beneficial Ownership Limitation' on warrants could restrict the ability to fully exercise and benefit from warrant holdings if the share price increases significantly, potentially leading to a forfeiture of rights or a need to reduce holdings.
• As a significant shareholder, Balyasny Asset Management L.P.'s investment decisions could influence market perception and stock price volatility.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Lexeo Therapeutics. It is a disclosure of beneficial ownership by Balyasny Asset Management L.P. and its affiliates.

Management Comments

• Each of the Reporting Persons has the sole power to vote or to direct the vote of 7,844,311 shares.
• Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 7,844,311 shares.
• ADMF and APHC, both Cayman Islands exempted companies that are investment management clients of BAM, have the right to receive dividends from, or the proceeds from the sale of, the reported securities.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Balyasny Asset Management L.P. is a well-known hedge fund, and its investment in Lexeo Therapeutics, a company likely in the biotechnology or pharmaceutical sector given its name, aligns with typical investment strategies in this space.

Related Party Transactions

• The filing details the relationships between Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, outlining how they collectively beneficially own the shares.
• ADMF and APHC are identified as investment management clients of BAM, and they have the right to receive dividends and proceeds from the sale of the reported securities.

Stakeholder Impact

• Shareholders: The significant stake held by Balyasny Asset Management L.P. may influence market sentiment and stock price. The 9.99% cap on warrant exercise could limit potential dilution or upside for other shareholders.
• Management: The filing indicates a substantial investor that is not seeking control, which may be viewed positively by current management.
• Creditors/Suppliers: No direct impact is indicated by this ownership disclosure.

Next Steps

• Balyasny Asset Management L.P. and its affiliates will continue to hold their shares in Lexeo Therapeutics, Inc.
• Future actions may include further adjustments to their stake, subject to the Beneficial Ownership Limitation and market conditions.
• Lexeo Therapeutics, Inc. will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

Lexeo Therapeutics, Balyasny Asset Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management, SEC Filing